Le Lézard
Classified in: Health
Subject: SVY

Global Orthobiologics Market to 2023: Focus on Allografts, Bone Morphogenic Proteins, Demineralised Bone Matrix, Synthetic Bone Grafts, Joint Fluid Therapy, Stem Cell Therapies & Soft Tissue Repair


DUBLIN, April 26, 2018 /PRNewswire/ --

The "Orthobiologics Market: Global Industry Analysis, Trends, Market Size and Forecasts up to 2023" report has been added to ResearchAndMarkets.com's offering.

Research and Markets Logo

The report predicts the global orthobiologics market to grow with a CAGR of 5.5% over the forecast period of 2017-2023.

The report on global orthobiologics market provides qualitative and quantitative analysis for the period of 2015 to 2023.

The report on orthobiologics market is a comprehensive study and presentation of drivers, restraints, opportunities, demand factors, market size, forecasts, and trends in the global orthobiologics market over the period of 2015 to 2023. Moreover, the report is collective presentation of primary and secondary research findings.

Porter's five forces model in the report provides insights into the competitive rivalry, supplier and buyer positions in the market and opportunities for the new entrants in the global orthobiologics market over the period of 2015 to 2023. Further, Growth Matrix given in the report brings an insight on the investment areas that existing or new market players can consider.


Key Topics Covered:

1. Preface
1.1. Report Description
1.2. Research Methods
1.3. Research Approaches

2. Executive Summary

3. Global Orthobiologics Market Overview
3.1. Introduction
3.2. Market Dynamics
3.2.1. Drivers
3.2.2. Restraints
3.2.3. Opportunities
3.3. Porter's Five Forces Analysis
3.4. Growth Matrix Analysis
3.5. Competitive Landscape in the Global Orthobiologics Market

4. Global Orthobiologics Market by Type
4.1. Allografts
4.2. Bone Morphogenic Proteins
4.3. Demineralised Bone Matrix
4.4. Synthetic Bone Grafts
4.5. Joint Fluid Therapy (Viscosupplementation)
4.6. Stem Cell Therapies
4.7. Soft Tissue Repair

5. Global Orthobiologics Market by Application
5.1. Spinal Fusion
5.2. Trauma Repair
5.3. Reconstructive Surgery
5.4. Soft-Tissue Injuries
5.5. Fracture Recovery

6. Global Orthobiologics Market by End-Use
6.1. Hospitals
6.2. Dental Clinics and Facilities
6.3. Research & Academic Institutes

7. Global Orthobiologics Market by Region 2017-2023

8. Company Covered
8.1. Zimmer Biomet Holdings, Inc.
8.2. DePuy Synthes
8.3. Stryker Corporation
8.4. Harvest Technologies Corporation
8.5. Globus Medical, Inc.
8.6. Orthofix International N.V.
8.7. Nuvasive, Inc.
8.8. Bioventus LLC
8.9. Kuros Biosciences Ltd.
8.10. Arthrex, Inc.

For more information about this report visit https://www.researchandmarkets.com/research/hnjct2/global?w=5


Media Contact:

Research and Markets
Laura Wood, Senior Manager
[email protected]  

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

 



SOURCE Research and Markets


These press releases may also interest you

at 23:15
Remedium Healthcare Products is proud to announce the launch of NuVeria Labs' revolutionary Sacral Silicone Dressing, now available for purchase on Amazon, bringing advanced wound care solutions directly to consumers' doorsteps. Designed to address...

at 18:50
Getting specialty medications into...

at 18:30
Arthrex, a global leader in minimally invasive surgical technology, has once again taken home prestigious medals for product innovation at the 37th annual Edison Awards. "This product, along with our other innovations,...

at 18:23
Aligned with the trend of immersive water therapy in 2024, Baros Maldives' Serenity Spa stands out as an oasis of indulgent spa and beauty rituals, boasting a 50-year legacy of luxury. Nestled within a tranquil sanctuary amidst the lush Maldivian...

at 17:55
Oragenics, Inc. , a company focused on developing unique, intranasal pharmaceuticals for the treatment of neurological disorders, today announced that it received a notice (the "Notice") from the NYSE American LLC (the "NYSE American") dated April...

at 17:20
Building on a successful phase one in which STChealth proved that the Universal Patient Identifier (UPI)?powered by Experian Health's Universal Identity Manager (UIM) and NCPDP Standardstm?can accurately identify patients across multiple datasets in...



News published on and distributed by: